Search results - 5 results
Pre-registration efficacy study of a novel marker vaccine against classical swine fever on Maternally Derived Antibody negative (MDA-) target animals.
candidate CP7_E2alf produced under Good Laboratory Practice (GLP) conditions by Pfizer was tested on 40 six-week-old MDA-piglets according to the European Pharmacopoeia (Ph.Eur.) requirements. Single doses of ...
Indirect foot-and-mouth disease vaccine potency testing based on a serological alternative.
serum titres of primo-vaccinated cattle and protection against infection have been proposed, but none have been accepted by the European Pharmacopoeia (Ph.Eur.) due to the lack of statistical power and ...
FMD vaccines: reflections on quality aspects for applicability in European disease control policy.
for prophylactic or emergency use, generally manufactured by the same basic methodology outlined in the OIE Manual and, for Europe, in the European Pharmacopoeia, and for the EU Member States in ...
Foot-and-mouth disease vaccine potency testing in cattle using homologous and heterologous challenge strains: precision of the "Protection against Podal Generalisation" test.
with VACC and VCON values of 65.7% and 59.2%, respectively. Results indicate that the homologous PPG test is more reliable than the European Pharmacopoeia potency test, but that a larger number of ...
European Pharmacopoeia foot-and-mouth disease vaccine potency testing in cattle: between test variability and its consequences.
p.3373-9 (2007) Keywords: Animals Cattle Dose-Response Relationship, Immunologic Europe Foot-and-Mouth Disease Virus Male Pharmacopoeias as Topic Reproducibility of Results Viral Vaccines Abstract: In the ...